ArticleFrontiers in public health2025
Epidemiological trends in burden of osteoarthritis in China: an analysis from 1990 to 2021 with forecasts for 2022-2050.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The Role of Myeloperoxidase in Osteoarthritis and Its Potential Modulation by Resveratrol: An Integrated Study.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Association of latent class trajectories of frailty with incident symptomatic knee osteoarthritis in Chinese postmenopausal women: a nationwide cohort study from China.Scientific reports · 2026Article
- Mitochondrial-targeted therapy for osteoarthritis: Challenges and opportunities from basic research to clinical translation.Frontiers in immunology · 2026Review
- Exploring Centrosome Amplification-Associated Biomarkers in Osteoarthritis Through Bioinformatics and Experimental Approaches.Journal of inflammation research · 2026Article
- 2050: An Arthroplasty Odyssey.Healthcare (Basel, Switzerland) · 2025Article
- Relationship between SPP1 (Osteopontin) and extracellular matrix dynamics: a comprehensive review.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the epidemiological trends in the burden of osteoarthritis (OA) in China from 1990 to 2021 and predict trends to 2050. Methods: The publicly accessible modeling data derived from the Global Burden of Disease Study 2021 were employed. The annual percent change and the annual average percentage change were calculated to analyze the trend in the burden of OA. The Age-Period-Cohort (APC) model was used to analyze the age, period, and cohort effects on the incidence, prevalence, and DALYs of OA. The decomposition method was employed to analyze the changes in the burden of OA from 1990 to 2021 in China. Spearman's correlation coefficients were used to assess correlations between the Age-Standardized Rates (ASRs) and the mean Age-Standardized prevalence from 1990 to 2021 in China. The Bayesian age-period cohort model was utilized to forecast the burden until 2050. Results: From 1990 to 2021, the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized disability-adjusted life years rate (ASDR) of OA in China all exhibited an upward trend. In 2021, the ASIR and ASPR were 554.61 per 100,000 (95% UI: 486.85-619.54) and 7,030.66 per 100,000 (95% UI: 6,211.20-7,831.69), respectively. The ASDR was 244.79 per 100,000 (95% UI: 117.30-491.91). The age-standardized rates of OA were higher among females than among males in 2021. In different age groups, the incidence rate reached its peak in the 50-54 age group for both sexes. The decomposition analysis showed that aging, population growth, and epidemiological changes were driving an increase in the disease burden of osteoarthritis in China. The increase in the ASRs of OA in China is closely linked to the rise in obesity rates. The prediction results indicated that the ASIR first increased and then decreased, while the ASPR and ASDR showed an upward trend. Conclusion: In the future, the burden of OA in China is likely to continue to grow. Greater attention should be given to females aged 50-54 years, and rational prevention and control measures should be formulated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.